Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Voriconazole is efficacious in treating acute IA and is proven and probable in 68 patients, and good responses were seen in 60% of those with pulmonary or tracheobronchial IA and 26% of allogeneic stem cell transplant recipients.
Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
The side-effects of standard antituberculosis therapy are frequent in hospitalized patients aged > or = 60 yrs or with a history of previous hepatitis, and are probably due to pyrazinamide rather than to isoniazid or rifampin.
Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function.
In acute infective exacerbations, Enterobacteriaceae and Pseudomonas spp are the predominant bacteria in patients with an FEV1 < or =35% of the predicted value.
Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.
Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.
Viral community-acquired pneumonia in nonimmunocompromised adults.
RVs are frequent etiologies of CAP (single or in combination with bacteria), and patients with chronic heart failure have an increased risk of acquiring a viral CAP.
Comparative Pharmacokinetics of Ciprofloxacin, Gatifloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, and Moxifloxacin after Single Oral Administration in Healthy Volunteers
- A. Lubasch, Ivonne Keller, K. Borner, P. Koeppe, H. Lode
- Biology, MedicineAntimicrobial Agents and Chemotherapy
- 1 October 2000
The five recently developed fluoroquinolones (gatifloxacin, grepaflox ACin, levofloxACin, moxiflOxacin), mox ifloxicin, and trovafl oxacin showed greater bioavailability, longer half-lives, and higher Cmaxs than ciprofloxac in an open, randomized, six-period crossover study.
Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care
- R. Erbes, K. Oettel, M. Raffenberg, H. Mauch, M. Schmidt-Ioanas, H. Lode
- Medicine, BiologyEuropean Respiratory Journal
- 1 June 2006
Data indicate a high mortality of patients with tuberculosis requiring intensive care unit care and identifies new independently associated risk factors.
Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis.
- A. Lubasch, Stefan Lück, T. Welte
- Medicine, BiologyThe Journal of antimicrobial chemotherapy
- 1 March 2003
The 2 x 7 h infusion of ceftazidime 2 g (C2 x 2) was clinically and bacteriologically as effective as the usual 3 x 2 g ceftzidime short-term infusion in the treatment of AECB, and demonstrated advantages in terms of pharmacodynamic parameters compared with the C3 x 2 regimen.
Pharmacokinetics of ciprofloxacin after oral and parenteral administration
- G. Höffken, H. Lode, C. Prinzing, K. Borner, P. Koeppe
- Medicine, BiologyAntimicrobial Agents and Chemotherapy
- 1 March 1985
In 12 fasting volunteers, the pharmacokinetics of ciprofloxacin were determined after the administration of 50, 100, and 750 mg orally as well as 50 and 100 mg intravenously over 15 min, indicating a first-pass effect of the liver.